Tools

LEADER 03398nam a2200541 i 4500

001 ssj0002710106;

003 WaSeSS;

005 20251212090320.0;

006 m d ;

007 cr n ;

008 220719s2023 flu sb 001 0 eng d;

010 a| 2022025600;

020 a| 9781003248156q| (ebook);

020 z| 9781032163444q| (hardback);

020 z| 9781032163482q| (paperback);

035 a| (WaSeSS)ssj0002710106;

042 a| pcc;

049 a| EREEa| NEHH;

050 00 a| RS420;

060 00 a| QW 805;

082 00 a| 615.1/92| 23/eng/20220907;

100 1 a| Niazi, Sarfaraz,d| 1949-?| UNAUTHORIZED;

245 10 a| mRNA therapeuticsh| [electronic resource] :b| fast-to-market strategies /c| Sarfaraz K. Niazi.;

250 a| First edition.;

260 a| Boca Raton :b| CRC Press,c| 2023.;

300 a| 1 online resource;

504 a| Includes bibliographical references and index.;

505 0 a| The genome machine -- Understanding nucleic acids -- RNA therapeutics -- Nucleoside vaccines -- cGMP mRNA vaccine manufacturing -- Regulatory guidance.;

506 a| Available only to authorized users.;

520 a| "This book is the most comprehensive and complete treatise on nucleic acid therapeutic products, including mRNA vaccines, their manufacturing, formulations, and testing for safety and efficacy testing. Details include cGMP-compliant manufacturing and regulatory filing steps. A new concept of "biosimilar" mRNA vaccine is presented to secure fast approval of copies of mRNA vaccines. Projections of financial plans to establish RNA manufacturing facilities are provided, along with details of supply chain management. Finally, the future of nucleic acid products in gene therapy and other newer applications is presented, along with a perspective that all new vaccines will be the nucleic acid type that will further provide first-time prevention of autoimmune disorders. It is projected that both big pharma and startups will enter this field, and we can expect significant additions to our drug armamentarium soon"--c| Provided by publisher.;

538 a| Mode of access: World Wide Web;

588 a| Description based on print version record and CIP data provided by publisher.;

650 12 a| mRNA Vaccinesx| standards?| UNAUTHORIZED;

650 22 a| Drug Developmentx| standards=| ^A1418907;

650 22 a| Technology, Pharmaceuticalx| methods=| ^A931864;

650 22 a| RNA, Messengerx| therapeutic use=| ^A952400;

655 0 a| Electronic books.=| ^A491897;

856 40 z| Full text available from Taylor & Francis eBooksu| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Fwww.taylorfrancis.com%2Fbooks%2F9781003248156;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 6677165;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6677165-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 12/19/2025x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6677165-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 12/19/2025x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 6677165-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 12/19/2025x| EBOOKz| JERESOURCE;

mRNA therapeutics fast-to-market strategies / Sarfaraz K. Niazi.

Author/creator	Niazi, Sarfaraz, 1949-
Format	Electronic
Edition	First edition.
Publication Info	Boca Raton : CRC Press, 2023.
Description	1 online resource
Supplemental Content	Full text available from Taylor & Francis eBooks
Subjects	mRNA Vaccines--standards. Drug Development--standards. Technology, Pharmaceutical--methods. RNA, Messenger--therapeutic use.

Contents	The genome machine -- Understanding nucleic acids -- RNA therapeutics -- Nucleoside vaccines -- cGMP mRNA vaccine manufacturing -- Regulatory guidance.
Abstract	"This book is the most comprehensive and complete treatise on nucleic acid therapeutic products, including mRNA vaccines, their manufacturing, formulations, and testing for safety and efficacy testing. Details include cGMP-compliant manufacturing and regulatory filing steps. A new concept of "biosimilar" mRNA vaccine is presented to secure fast approval of copies of mRNA vaccines. Projections of financial plans to establish RNA manufacturing facilities are provided, along with details of supply chain management. Finally, the future of nucleic acid products in gene therapy and other newer applications is presented, along with a perspective that all new vaccines will be the nucleic acid type that will further provide first-time prevention of autoimmune disorders. It is projected that both big pharma and startups will enter this field, and we can expect significant additions to our drug armamentarium soon"-- Provided by publisher.
Bibliography note	Includes bibliographical references and index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Source of description	Description based on print version record and CIP data provided by publisher.
Issued in other form	Print version: Niazi, Sarfaraz, 1949- mRNA therapeutics First edition. Boca Raton : CRC Press, 2023 9781032163444
Genre/form	Electronic books.
LCCN	2022025600
ISBN	9781003248156 (ebook)
ISBN	(hardback)
ISBN	(paperback)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

mRNA therapeutics fast-to-market strategies / Sarfaraz K. Niazi.

Click here for more information about this title

Availability